Close Menu

NEW YORK – Baxter International said on Wednesday that it has inked a distribution agreement with BioMérieux for its Nephroclear CCL14 diagnostic test currently in development for use in assessing the risk of developing persistent sever acute kidney injury (AKI).

Specifically, Baxter will be the exclusive distributor of the assay in Europe and the US following regulatory approval and launch in those markets. The companies will share in-country commercialization, while BioMérieux will retain control over the regulatory process. Financial terms of the agreement were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.